Down 75%. Is Agenus Stock a Buy on the Dip? [Yahoo! Finance]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Yahoo! Finance
Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target. Agenus shares could deliver an enormous return if they get anywhere near Wall Street estimates. The stock has been trading below $1 per share since the company presented clinical trial results for its lead candidate last October. Let's weigh arguments for buying Agenus against the apparent risks to see if it's a smart buy at its beaten-down valuation. Reasons to buy beaten-down Agenus stock These days, Agenus is a clinical-stage cancer drug developer without any approved products to sell, but this wasn't always the case. It developed an adjuvant that is part of GSK 's Shingrix vaccine. Agenus sold rights to royalties from the Shingrix vaccine years ago, but it still receives occasional cash injections from big pharma partners. For example, Bristol M
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Up 40%: Is This Red-Hot Growth Stock Still a Buy? [Yahoo! Finance]Yahoo! Finance
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingBusiness Wire
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Agenus to Provide First Quarter 2024 Financial Report and Corporate UpdateBusiness Wire
AGEN
Earnings
- 3/14/24 - Miss
AGEN
Analyst Actions
- 3/18/24 - HC Wainwright
AGEN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/22/24 - Form 4
- AGEN's page on the SEC website